Inhibition of the growth of human melanoma metastases in nude mice by melanoma-specific murine monoclonal antibody.

Published

Journal Article

The administration of anti-melanoma murine monoclonal antibody (MAB) 16.C8 (IgG2a) to nude mice bearing established human melanoma lung or liver metastases resulted in a significant inhibition of tumour growth. A total dose of 2 mg of affinity purified 16.C8 caused complete inhibition of tumour growth in 89 and 100% of animals in the liver and lung model, respectively. In contrast, a significant tumour growth was found in most control animals which received an irrelevant IgG2a MAB or 2% human serum albumin in Hanks Balanced Salt Solution (HBSS). The MAB was most effective when treatment was started on day 1 or 4 following tumour inoculation. When the 16.C8 MAB treatment was delayed 7 or 14 days, 33 and 67% of 16.C8 treated animals, respectively, developed tumours. The MAB-mediated anti-tumour activity appeared to be dose dependent, and the effect of a suboptimal dose was potentiated by the concomitant administration of recombinant interleukin 2 (rIL-2). Recombinant IL-2 alone in a similar dose did not elicit comparable anti-tumour activity. Moreover, the MAB 16.C8 inhibited tumour growth in irradiated animals which may suggest the involvement of host-radioresistant cellular elements in the 16.C8 antibody-mediated anti-tumour activities in nude mice. These results suggest that MAB 16.C8 alone or combined with rIL-2 may prove useful in the immunotherapy of metastatic melanoma.

Full Text

Duke Authors

Cited Authors

  • Abdel-Wahab, ZA; Darrow, TL; Vervaert, CE; Giannopoulou, AA; Li, W; Seigler, HF

Published Date

  • April 1, 1992

Published In

Volume / Issue

  • 1 / 2

Start / End Page

  • 115 - 125

PubMed ID

  • 1341242

Pubmed Central ID

  • 1341242

International Standard Serial Number (ISSN)

  • 0960-7404

Digital Object Identifier (DOI)

  • 10.1016/0960-7404(92)90024-f

Language

  • eng

Conference Location

  • Netherlands